Mind Medicine Stock Today

MNMD Stock  USD 5.17  0.08  1.52%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 26

 
High
 
Low
Below Average
Mind Medicine is trading at 5.17 as of the 11th of October 2024, a 1.52 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.08. Mind Medicine has about a 26 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Mind Medicine are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of August 2024 and ending today, the 11th of October 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of March 2020
Category
Healthcare
Classification
Health Care
Mind Medicine Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company has 81.43 M outstanding shares of which 10.36 M shares are now shorted by private and institutional investors with about 13.34 trading days to cover. More on Mind Medicine

Moving together with Mind Stock

  0.81ME 23Andme HoldingPairCorr

Moving against Mind Stock

  0.84VCYT VeracytePairCorr
  0.74DMAC DiaMedica TherapeuticsPairCorr
  0.7DRTS Alpha Tau MedicalPairCorr
  0.62VERA Vera TherapeuticsPairCorr
  0.61A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr
  0.56DNLI Denali TherapeuticsPairCorr

Mind Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Executive PresidentMiriam Wernli
Thematic IdeaBiotech (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities33.9 M32.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total14.9 M14.2 M
Sufficiently Up
Slightly volatile
Total Assets119.5 M124.5 M
Sufficiently Down
Slightly volatile
Total Current Assets103.8 M103.9 M
Slightly Down
Slightly volatile
Debt Levels
Mind Medicine can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mind Medicine's financial leverage. It provides some insight into what part of Mind Medicine's total assets is financed by creditors.
Liquidity
Mind Medicine currently holds 14.13 M in liabilities. Mind Medicine has a current ratio of 13.58, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Mind Medicine's use of debt, we should always consider it together with its cash and equity.

Change In Cash

(40.32 Million)
Mind Medicine (MNMD) is traded on NASDAQ Exchange in USA. It is located in One World Trade Center, New York, NY, United States, 10007 and employs 57 people. Mind Medicine is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 421 M. Mind Medicine conducts business under Biotechnology sector and is part of Health Care industry. The entity has 81.43 M outstanding shares of which 10.36 M shares are now shorted by private and institutional investors with about 13.34 trading days to cover. Mind Medicine currently holds about 105.74 M in cash with (64.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71.
Check Mind Medicine Probability Of Bankruptcy
Ownership Allocation
Mind Medicine maintains a total of 81.43 Million outstanding shares. Over half of Mind Medicine's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mind Ownership Details

Mind Stock Institutional Holders

InstituionRecorded OnShares
Woodline Partners Lp2024-06-30
M
Ally Bridge Group (ny) Llc2024-06-30
965.4 K
Awm Investment Company Inc2024-06-30
833 K
Two Sigma Investments Llc2024-06-30
683.7 K
Charles Schwab Investment Management Inc2024-06-30
556.4 K
Tri Locum Partners Lp2024-06-30
382.1 K
Bank Of New York Mellon Corp2024-06-30
246.2 K
Nuveen Asset Management, Llc2024-06-30
204.1 K
Northern Trust Corp2024-06-30
183.9 K
Commodore Capital Lp2024-06-30
7.1 M
Deep Track Capital, Lp2024-06-30
6.1 M
View Mind Medicine Diagnostics

Mind Medicine Historical Income Statement

At present, Mind Medicine's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 5.1 M, whereas Operating Income is projected to grow to (89.2 M). View More Fundamentals

Mind Stock Against Markets

Mind Medicine Corporate Management

MD MAChief OfficerProfile
Schond MBAChief OfficerProfile
Maxim CFAVice CommunicationsProfile
Wong JDChief SecProfile
MD MBAChief OfficerProfile
Mark JDChief SecretaryProfile
When determining whether Mind Medicine is a strong investment it is important to analyze Mind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mind Medicine's future performance. For an informed investment choice regarding Mind Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mind Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mind Medicine. If investors know Mind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.04)
Return On Assets
(0.28)
Return On Equity
(0.66)
The market value of Mind Medicine is measured differently than its book value, which is the value of Mind that is recorded on the company's balance sheet. Investors also form their own opinion of Mind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Mind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mind Medicine's market value can be influenced by many factors that don't directly affect Mind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.